CombiGene AB

COMBI

SE0016101935

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 08:43:30 24/05/2024 pm IST			5-day change	1st Jan Change
3.15 ^SEK	-3.67%		-6.25%	+17.10%

23/05	CombiGene AB Approves Election of Marcus Isaksson as Board Member	CI
17/05	CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Combigene AB Appoints Gunilla Lundmark as Board Member of the Company

May 25, 2021 at 02:45 pm IST

CombiGene AB (publ), at its AGM held on May 25, 2021, appointed Gunilla Lundmark as board member.

Latest news about CombiGene AB

CombiGene AB Approves Election of Marcus Isaksson as Board Member	23/05	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2024	17/05	CI
CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	13/03	CI
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	21/02	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	16/02	CI
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
CombiGene Taps Charles River Laboratories as Clinical Research Partner for Pain Project	01/11	MT
Combigene AB Chooses Charles River as Preclinical Toxicology Partner for COZY01 Pain Project	31/23/31	CI
CombiGene, Zyneyro to Start Clinical Studies of COZY01 Targeting Shingles	26/23/26	MT
CombiGene AB and Zyneyro Choose Initial Indication in the Cozy01 Pain Project	26/23/26	CI
Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	15/23/15	CI
CombiGene AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/23/25	CI
CombiGene CEO to Depart in September	30/23/30	MT
CombiGene AB Announces Chief Executive Officer Changes	30/23/30	CI
Combigene AB to Play an Integrate Part in the Development of National Infrastructure for ATMPs	24/23/24	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	17/23/17	CI
Combigene Enters into Collaboration Agreement with Zyneyro for the Development of A Unique Concept for Effective Relief of Chronic Pain	09/23/09	CI
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Combigene AB Appoints Peter Ekolind as COO	27/22/27	CI
CombiGene AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	25/22/25	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2022	12/22/12	CI
CombiGene AB Signs Agreement with A Potential Value of USD 328.5 Million with Spark Therapeutics	21/22/21	CI
CombiGene AB Reports Earnings Results for the Full Year Ended December 31, 2021	17/22/17	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	17/22/17	CI

Combigene AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.

Sector

Biotechnology & Medical Research

Calendar

23/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
COMBIGENE AB	+17.10%	58.58L
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	12TCr
REGENERON PHARMACEUTICALS, INC.	+12.15%	11TCr
BIONTECH SE	-8.14%	2.34TCr
ARGENX SE	-1.69%	2.18TCr
GENMAB A/S	-10.60%	1.81TCr
WUXI APPTEC CO., LTD.	-41.25%	1.67TCr
BEIGENE, LTD.	-15.33%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+5.80%	1.4TCr
SAREPTA THERAPEUTICS, INC.	+28.03%	1.17TCr